Is Buying Aptose Biosciences Inchares (NASDAQ:APTO), Having Lower Short Interest a Winning Strategy?

May 16, 2018 - By Linda Rogers

The stock of Aptose Biosciences Inchares (NASDAQ:APTO) registered a decrease of 23.28% in short interest. APTO’s total short interest was 403,700 shares in May as published by FINRA. Its down 23.28% from 526,200 shares, reported previously. With 289,800 shares average volume, it will take short sellers 1 days to cover their APTO’s short positions.

The stock increased 0.33% or $0.011 during the last trading session, reaching $3.301. About 156,023 shares traded. Aptose Biosciences Inc. (NASDAQ:APTO) has risen 188.70% since May 16, 2017 and is uptrending. It has outperformed by 177.15% the S&P500.

Aptose Biosciences Inc., a clinical-stage biotechnology company, discovers and develops personalized therapies addressing unmet medical needs in oncology in Canada. The company has market cap of $102.48 million. The Company’s lead clinical program is APTO-253, which is a Phase I clinical trial for the treatment of patients with relapsed or refractory hematologic malignancies. It currently has negative earnings. The firm has an agreement with CrystalGenomics, Inc. to research, develop, and commercialize CG026806, a non-covalent small molecule therapeutic agent, which is in preclinical stage for the treatment of acute myeloid leukemia and chronic lymphocytic leukemia/mantle cell lymphoma.

Aptose Biosciences Inc. (NASDAQ:APTO) Ratings Coverage

Among 2 analysts covering Aptose Biosciences (NASDAQ:APTO), 2 have Buy rating, 0 Sell and 0 Hold. Therefore 100% are positive. Aptose Biosciences had 5 analyst reports since December 13, 2017 according to SRatingsIntel. The rating was maintained by H.C. Wainwright with “Buy” on Wednesday, March 28. The company was maintained on Monday, May 7 by H.C. Wainwright. The stock of Aptose Biosciences Inc. (NASDAQ:APTO) earned “Buy” rating by H.C. Wainwright on Wednesday, December 13. H.C. Wainwright maintained the shares of APTO in report on Monday, April 16 with “Buy” rating. On Monday, April 16 the stock rating was maintained by Roth Capital with “Buy”.

More notable recent Aptose Biosciences Inc. (NASDAQ:APTO) news were published by: Nasdaq.com which released: “Aptose Presents Preclinical Data on APTO-253 at 2018 AACR Annual Meeting” on April 17, 2018, also Globenewswire.com with their article: “Aptose Exercises Early Option for CG-806 License From CrystalGenomics” published on May 07, 2018, Benzinga.com published: “25 Stocks Moving In Tuesday’s Pre-Market Session” on May 15, 2018. More interesting news about Aptose Biosciences Inc. (NASDAQ:APTO) were released by: Seekingalpha.com and their article: “Aptose Biosciences’ (APTO) CEO William Rice on Q1 2018 Results – Earnings Call Transcript” published on May 11, 2018 as well as Investingnews.com‘s news article titled: “Aptose Provides Molecule Update and Q1 Financial Results” with publication date: May 16, 2018.

Aptose Biosciences Inc. (NASDAQ:APTO) Ratings Chart

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our daily email newsletter.

Free Email Newsletter

Enter your email address below to get the latest news and analysts' ratings for your stocks with our FREE daily email newsletter: